Therapy for organic erectile dysfunction;Therapie der organogen bedingten erektilen dysfunktion

Urologe - Ausgabe A

Volumn 44, Issue 10, 2005, Pages 1160-1166

  Becker, A J ^a   Mayer, M ^a   Stief, C G ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anti serotoninergic substrates; Erectile dysfunction; Growth hormone; Penile implants; Prostaglandin E1; Sildenafil; Tadalafil; Testosterone; Therapy; Vacuum erectile devices; Vardenafil; Yohimbine

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; CLOMIPRAMINE; FLUOXETINE; GROWTH HORMONE; HUMAN GROWTH HORMONE; KETANSERIN; MELANOCORTIN RECEPTOR; MIANSERIN; N ACETYLNORLEUCYLASPARTYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHYLLYSINE 2,7 CYCLIC AMIDE; OXYTOCIN; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; PROTEIN INHIBITOR; SEROTONIN ANTAGONIST; SILDENAFIL; SOMATOMEDIN C; SPIEGEL; TADALAFIL; TESTOSTERONE; TESTOSTERONE UNDECANOATE; TRAZODONE; UNCLASSIFIED DRUG; VARDENAFIL; YOHIMBINE;

ANAMNESIS; ARTICLE; COMORBIDITY; DEVICE; DIAGNOSTIC PROCEDURE; ERECTILE DYSFUNCTION; HUMAN; LABORATORY TEST; LIVER TOXICITY; MEDICAL EXAMINATION; PATIENT SATISFACTION; PENIS PROSTHESIS; PHYSICAL EXAMINATION; PREVALENCE; PSYCHOTHERAPY; QUALITY OF LIFE; TREATMENT CONTRAINDICATION; TREATMENT PLANNING; VACUUM;

GERMANY; HUMANS; IMPOTENCE; MALE; PENILE PROSTHESIS; PHOSPHODIESTERASE INHIBITORS; PHYSICAL STIMULATION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PSYCHOTHERAPY; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; VACUUM;

EID: 26844467250     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-005-0910-9     Document Type: Article

References (39)

1. Aytac, Mckinlay, Krane (1999) The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 84: 50-56
2. Sperling H, Hartmann U, Weidner W, Stief CG (2005) Erektile Dysfunktion. Pathophysiologie, Diagnostik und Therapie. Dtsch Ärzteblatt 102(23): 1397-1402
3. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ (1996) Use of Sildenafil (Viagra) in Patients With Cardiovascular Disease. Br J Urol 8: 257-261
4. Guay AT, Perez JB, Jacobson J, Newton RA (2001) Efficacy and Safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl 22: 793-797
5. Pryor JP (2002). Vardenafil update on clinical experience. Int J Impot Res 14(Suppl 1): 65-69
6. Sperling H, Lümmen G, Schneider T, Rübben H (2003) Neue Therapieoptionen zur Behandlung der ED. Herz 28: 314-324
7. Jünemann KP (2003).Wie wirksam sind die PDE-5-Hemmstoffe? Urologe A 42(4): 553-558
8. Montorsi F, Salonia A, Deho,F, Cestari A, Guazzoni G, Rigatti P, Stief C(2003) Pharmacological management of erectile dysfunction. BJU 91(5): 446
9. Mc Mahon C (2004) Efficacy and safety on daily tadalafil men with erectile dysfunction previously unresponsive to on demand tadalafil. J Sex Med 1: 292-300
10. Goldstein J, Lue TF, Padma NH, Rosen RC, Steers WD (1998) Oral sildenafil in the treatment of erectile dysfunction. Sildenafil study group. N Engl J Med 338: 1397-404
11. Buono Lm, Foroozan R, Sergott RC, Sauno PJ (2002) Nonarteriitic anterior ischemic optic neuropathy. Curr Opin Opthalmology 13: 357-361
12. Galitzky J, Riviere D, Tran MA, Montastruc JL, Berlan M (1990) Pharmacodynamic effects of chronic yohimbine treatment in healthy volunteers. Eur j Clin Pharmacol 39(5): 447-451
13. Porst H (2005) Der alternde Mann im Spiegelbild der Hormone. (zur Veröffentlichung eingereicht)
14. CG Stief, U Hartmann, MC Truss (2002) Zeitgemäße Therapie der erektilen Dysfunktion, 2. Aufl. Springer, Berlin Heidelberg New York Tokio
15. Anderson KE (2000). Neurotransmitters: Central and peripheral mechanism. Int J Impot Res 12: 30-33
16. J Fabrizio (2005) Histological alterations in cavernous tissue after radical prostatectomy. J Urol 173: 5
17. Derouet H, Zehl U (1993) Treatment of erectile dysfunction with vacuum pumps. Urologe A 32: 312-315
18. Althoff SE, Turner LA, Levine SB, Bodner D, Kursh ED, Resnick MI (1992) Through the eyes of woman: the sexual and psychological responses of woman to their partners treatment with self injection or external vacuum therapy. J Urol 147: 1024-1027
19. Manning M, Spahn M, Jünemann KP (1998) Gefäß chirurgie, Implantationschirurgie und Vakuumerektionshilfen. Urologe A 37: 509-515
20. Rehmann J, Kaynan A, Christ G, Valcic M, Maayani S, Melman A (1999) Modification of sexual behaviour of Long-Evans male rats by drugs acting on the 5-HAT 1A receptor. Brain Res 821: 414-425
21. Tang Y, Rampin O, Calas A, Facchinetti P, Guiliano F (1998) Oxytocinergic and serotonergic innervation of identified lumbosacral nuclei controlling penile erection in the male rat. Neuroscience 82: 241-254
22. Witt MA, Grantmyre JE (1993) Ejaculatory failure. World J Urol 11: 89-95
23. Svensson L, Hansen S (1984) Spinal monoaminergic modulation of masculine copulatory behaviour n the rat. Brain Res 302: 315-321
24. Gorzalka BB, Mendelson SD, Watson NV (1990) Serotonin receptor subtypes and sexual behaviour. Ann NY Acad Sci 600: 445-446
25. Aizenberg D, Gur S, Zemishlany Z, Granek M, Jeczmien P, Weizman A (1997) Mianserin, a 5-HT "A/2C and alpha 2 antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol 20: 210-214
26. Mizusawa H, Hedlund P, Brioni JD, Sullivan JP, Andersson K-E (2002) Nitrit oxid independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. J Urol 167: 2276-2281
27. Nakane M, Hsieh G, Miller LN et al. (2002) Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: Synergism of nitric oxideand YC-1. Int J Impot Res 14: 121-127
28. Kuensch E, Reiners K, Müller-Mattheis V, Strohmeyer T, Ackermann R, Freund H-J (1992) Neurological risk profile in organic erectile dysfunction. J Neurol Neurosurg Psych 55: 275-281
29. Becker AJ, Ückert S, Stief CG, Scheller F, Knapp WH, Hartmann U, Jonas U (2002) Cavernous and systemic plasma levels of norepinephrine and epinephrine during differentpenile conditions in healthy males and patients with erectile dysfunction. Urology 59: 281-286
30. Krane RJ, Goldstein I, Saenz de Tejada I (1989) Medical progress: Impotence. N Eng J Med 321: 1648-1659
31. Goldstein I and the VASOMAX Study Group (1998) Efficacy and safety of oral phentolamine (VASOMAX) for the treatment of minimal erectile dysfunction. J Urol 159(Suppl): 240
32. Goldstein I (1999) First-line therapy: alpha-adrenergic receptor antagonists-clinical. Podium presebtation: Master Course in erectile dysfunction. Boston MA, USA, 29.06.-30.06.1999, Coordinated by the Ithaka Center for postgraduate Medical Education
33. Argiolas A, Melis MR, Gessa GL (1988) Yawning and penile erection:central dopamine-oxytocin-adrenocorticotropin connection. Ann NY Acad Sci 525: 330-337
34. Vergoni AV, Bertolini P, Wikberg JE, Schioth HB (1998) Differential influenche on a selective melanocortin MC4 receptor antagonist (HS014) on melanocortin- induced behavioural effects in rats. Eur J Pharmacol 362: 95-101
35. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD (1992) The cloning of a family of genes that encode the melanocortin receptors. Science 257: 1248-1251
36. Hull KL, Harvey S (2000): Growth hormone: a reproductive endocrine-paracrine regulator. Rev Reprod 5: 175-182
37. Jung GW,Spencer EM, Lue TF (1998) Growth hormone enhances regeneration of nitric-oxide synthase-containing penile-nerves after cavernous nerve neurotomy in rats. J Urol 160: 1899-1904
38. Gorge F, Fluchter S, Kirstein M, Kunz T(2003) Sex, erectile dysfunction, and the heart: a growing problem. Herz 28(4): 284-290
39. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellika A (2002) Cardiovascular effects of sildenafil duringexercise in men with known or propable coronary artery disease. JAMA 287: 719-725